Literature DB >> 8706483

N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock.

S L Peake1, J L Moran, P I Leppard.   

Abstract

OBJECTIVE: To investigate the effects of adjunctive therapy with parenteral N-acetyl-L-cysteine in patients with newly diagnosed septic shock.
DESIGN: Prospective, randomized, double-blind, placebo-controlled study.
SETTING: Multidisciplinary intensive care unit at a university teaching hospital. PATIENTS: Twenty patients (N-acetyl-L-cysteine group [n = 10], placebo group [n = 10]), 15 male and five female, of mean age 64 +/- 15 (SD) yrs and Acute Physiology and Chronic health Evaluation (APACHE) II score 33 +/- 6, with septic shock within 24 hrs of diagnosis.
INTERVENTIONS: After a 2-hr stabilization period (time-zero minus 2 hrs to time-zero), patients received either N-acetyl-L-cysteine in 5% dextrose (150 mg/kg in 100 mL over 15 mins, followed by 50 mg/kg in 250 mL over 4 hrs, and then 100 mg/kg/24 hrs in 500 mL for 44 hrs; N-acetyl-L-cysteine group) or the equivalent volume of 5% dextrose (placebo group).
MEASUREMENTS AND MAIN RESULTS: Hemodynamic and oxygen transport indices were measured at time-zero minus 2 hrs and time-zero, and at multiple time points thereafter until completion of the trial infusion (time-zero plus 48 hrs). A daily Organ Failure Score was recorded for 14 days. Treatment group demographics and hemodynamic variables did not differ significantly between the two groups at time-zero. Mean (SD), pooled mean arterial pressure (MAP), and cardiac index were 75 +/- 15 mm Hg and 3.9 +/- 1.2 L/min/m2, respectively. Over the next 48 hrs, in the N-acetyl-L-cysteine group, there was a progressive decrease, relative to both time-zero and the placebo group, in MAP, cardiac index, and left ventricular stroke work index (p < .01, repeated-measures analysis of variance). Percentage reductions in these values relative to the placebo group at 48 hrs were 23%, 18%, and 43%, respectively Oxygen transport indices, arterial blood gas analyses, Pao2/Fio2 ratio, and shunt did not differ over time between the groups. There was no difference in either daily Organ Failure Score over time (p > .01, repeated-measures analysis of variance) or hospital mortality rate (90% N-acetyl-L-cysteine group, 50% placebo group) (p > .1, logistic regression) between the two groups.
CONCLUSION: Adjunctive therapy with N-acetyl-L-cysteine in newly diagnosed septic shock was associated with a depression in cardiovascular performance, as indicated by progressive reductions in cardiac index, left ventricular stroke work index, and MAP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706483     DOI: 10.1097/00003246-199608000-00006

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  20 in total

1.  Closed-loop vasopressor control: in-silico study of robustness against pharmacodynamic variability.

Authors:  Joseph Rinehart; Alexandre Joosten; Michael Ma; Michael-David Calderon; Maxime Cannesson
Journal:  J Clin Monit Comput       Date:  2018-12-11       Impact factor: 2.502

2.  The effect of N-acetylcysteine on total serum anti-oxidant potential and urinary albumin excretion in critically ill patients.

Authors:  Z Molnar; K L MacKinnon; E Shearer; D Lowe; I D Watson
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

3.  Prophylactic N-acetylcysteine decreases serum CRP but not PCT levels and microalbuminuria following major abdominal surgery. A prospective, randomised, double-blinded, placebo-controlled clinical trial.

Authors:  Zsolt Molnar; Tamas Szakmany; Tamas Koszegi
Journal:  Intensive Care Med       Date:  2003-04-08       Impact factor: 17.440

4.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

5.  NOX2 protects against progressive lung injury and multiple organ dysfunction syndrome.

Authors:  Laura C Whitmore; Kelli L Goss; Elizabeth A Newell; Brieanna M Hilkin; Jessica S Hook; Jessica G Moreland
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-05-02       Impact factor: 5.464

Review 6.  Etiology and management of fulminant hepatic failure.

Authors:  Javier Vaquero; Andres T Blei
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 7.  Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.

Authors:  Michael Joannidis; Wilfred Druml; Lui G Forni; A B Johan Groeneveld; Patrick Honore; Heleen M Oudemans-van Straaten; Claudio Ronco; Marie R C Schetz; Arend Jan Woittiez
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

Review 8.  N-acetylcysteine for sepsis and systemic inflammatory response in adults.

Authors:  Tamas Szakmany; Balázs Hauser; Peter Radermacher
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 9.  Hemodynamic goals in randomized clinical trials in patients with sepsis: a systematic review of the literature.

Authors:  Jonathan E Sevransky; Seema Nour; Gregory M Susla; Dale M Needham; Steven Hollenberg; Peter Pronovost
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 10.  Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock.

Authors:  Pierre Asfar; Daniel De Backer; Andreas Meier-Hellmann; Peter Radermacher; Samir G Sakka
Journal:  Crit Care       Date:  2003-12-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.